Studies in pediatric AML have shown a negative correlation of IDO-1 mRNA expression with outcomes, supporting the idea that these patients can potentially benefit from specific IDO-1 inhibitor therapies [138]. Here, IDO1 is linked to acute myeloid leukemia.